Table 4.
Adverse events in selected trial of bevacizumab in colorectal cancer
| Kabbinavar 200347 | Hurwitz 20049 | Kabbinavar 200557 | AVIRI 200852 | TREE 254 | ECOG 320056 | Saltz 200855 | First BEAT60 | BRITE (long term f/u)96,97,101,102 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BV 5 mg/kg | BV 10 mg/kg | BV 5 mg/kg | BV 5 mg/kg | Irinotecan + LV + 5-FU + BV 5 mg/kg | FOLFOX + BV 5 mg/kg | bFOL + BV 5 mg/kg | CapOX + BV 5 mg/kg | FOLFOX4 + BV 10 mg/kg | BV 10 mg/kg | BV 7.5 mg/kg + FOLFOX4 or XELOX | FOLFOX/FOLFIRI/XELOX/5FU/Cap + BV 5–7.5 mg/kg | ||
| HTN – any grade (%) | 11 | 28 | 22.4 | 32 | NR | NR | NR | NR | NR | NR | NR | 29.9 | 27.5 |
| Grade 3 or 4 HTN (%) | 8.6 | 25 | 11 | 16 | 3.8 | 5.82 | 6.2 | 7.3 | 4 | 5.3 | NR | ||
| Proteinuria – any grade (%) | 22.8 | 28.1 | 26.5 | 38 | NR | NR | NR | NR | NR | NR | NR | 10.4 | NR |
| Grade 3 or 4 Proteinuria (%) | NR | NR | 0.8/0 | 1/0 | NR | 0.89 | 0.7 | 0 | <1 | 1.1 | NR | ||
| ATE (%) | 2.85 | 6.25 | NR | 10 | 4.3 | 0 | 0 | 5.55 | NS | 2 | 1.5 | 2 | |
| Grade 3 or 4 bleeding (%) | 0 | 9.4 | 3.1 | 5 | 3.8 | 3 | 0 | 0 | 3.4 | 2.1 | 2 | 3.4 | 2.5 |
| GI perforation (%) | NR | NR | 1.5 | 2 | NR | 2.24 | 1.04 | 1.04 | <1 | 1.8 | 2 | ||
| Wound healing (%) | NR | NR | NR | NR | NR | 1.34 | NR | NR | <1 | 1.1 | 3.7 | ||
Abbreviations: HTN, hypertension; ATE, arterial thrombo embolic events; GI, gastrointestinal; NR, not reported, NS, non-significant; BV, bevacizumab.